NEW YORK (GenomeWeb) – Novogene, a Beijing-based sequencing service provider that was founded in 2011, is looking to enter the clinical next-generation sequencing market with two cancer panels that it has submitted to the China Food and Drug Administration (CFDA) for approval, officials said this week.
The company currently offers two research-only tests, a hotspot panel and a larger panel that assesses mutations in just under 500 genes. It has validated both panels to run on either Thermo Fisher Scientific’s Ion Proton or Illumina’s NextSeq, CEO Ruiqiang Li told GenomeWeb.
The company is also working on a hereditary cancer panel and has plans to develop a noninvasive prenatal test.
Aside from the NextSeq and Proton, Novogene provides sequencing services for research on the Illumina HiSeq X Ten system, the HiSeq 4000 and 2500, and the MiSeq, Li said.
VIEW THE FULL ARTICLE »
The field is required.